Commerzbank Aktiengesellschaft’s Biogen BIIB Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$102K	–	858
2019 Q2	$102K	Buy	+10,000	New	+$2.31M	﹤0.01%	985
2018 Q4	–	Sell	-5,000	Closed	-$210K	–	972
2018 Q3	$210K	Buy	+5,000	New	+$1.72M	﹤0.01%	874
2018 Q1	–	Sell	-7,875	Closed	-$220K	–	948
2017 Q4	$220K	Buy	7,875 +5,000	+174%	+$1.6M	﹤0.01%	818
2017 Q3	$900K	Buy	+2,875	New	+$851K	0.01%	488
2017 Q1	–	Sell	-4,757	Closed	-$1.35M	–	928
2016 Q4	$1.35M	Buy	+4,757	New	+$1.41M	0.02%	389
2015 Q1	–	Sell	-12,600	Closed	-$4.28M	–	1157
2014 Q4	$4.28M	Hold	12,600	–	–	0.03%	452
2014 Q3	$4.17M	Buy	12,600 +8,000	+174%	+$2.64M	0.02%	546
2014 Q2	$1.45M	Hold	4,600	–	–	0.01%	776
2014 Q1	$1.41M	Sell	4,600 -5,600	-55%	-$1.78M	0.01%	777
2013 Q4	$3.19M	Buy	10,200 +600	+6%	+$155K	0.02%	613
2013 Q3	$2.31M	Sell	9,600 -200	-2%	-$44.8K	0.01%	687
2013 Q2	$2.11M	Buy	+9,800	New	+$2.09M	0.01%	754

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Commerzbank Aktiengesellschaft's BIIB Position: Q2 2020 in Review

Commerzbank Aktiengesellschaft sold out of Biogen (BIIB) in Q2 2020, closing a stake of 4,670 shares — an estimated $1.48M sold.

Commerzbank Aktiengesellschaft first reported a position in BIIB in Q2 2013 and held it in 28 quarters. The position peaked at $80.3M in Q2 2015. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Commerzbank Aktiengesellschaft reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Commerzbank Aktiengesellschaft sold 4,670 Biogen shares in Q2 2020, an estimated $1.48M.
Commerzbank Aktiengesellschaft first reported a position in Biogen in Q2 2013 and held it in 28 quarters.
Commerzbank Aktiengesellschaft's Biogen position peaked at $80.3M in Q2 2015.
1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2020, filed 21 Jul 2020.